Bioventix plc is a UK-based biotechnology company, which primarily develops and supplies high-affinity SMAs (sheep monoclonal antibodies) to be utilised in immunodiagnostics. It was founded in the year 2003, and its headquarters are situated in Farnham, United Kingdom. The company is listed and traded on the Alternative Investment Market (AIM) of the London Stock Exchange since 2014.
The strategy of the company is to recognise prevailing or new commercial assays, which are in need of improved antibodies. In the conventional rodent monoclonal antibodies, the target is at low concentration, the target is a short peptide sequence, or the target is a drug or small molecule. The company provides high-affinity antibodies, which has a variety of benefits as compared to these conventional antibodies, thus tackling the drawbacks of other antibodies. The high-affinity SMAs have the potential to enhance precision and assay sensitivity in many assay formats. Bioventix has been able to develop SMAs in cases where conventional antibodies have not been able to produce suitable reagents. The company supplies its products to mostly all the multinational immunodiagnostics companies present worldwide.
The products are available for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious diseases, and oncology etc. The core services offered by the company include antibody creation, which includes creating high-affinity SMAs, sheep immunization, Screening and selecting the high-affinity sub-clones, and dealing with low concentration targets, like steroids. Production and assay services are also offered by the company, which include mass production of SMAs with the help of hollow fibre bioreactors and flask culture, utilising immunoaffinity chromatography for purification purposes, protein electrophoresis, Immunoassay (ELISA), and HPLC analysis of purified antibodies. The antibodies are developed by the company using the latest technology, such that they have ultra-high affinity, broader epitope recognition, improved sensitivity as well as specificity.
Bioventix plc follows a well-defined framework of corporate governance and aligns itself with the Quoted Companies Alliance (QCA) Corporate Governance Code. The board of the company has set up separate committees for audit and risk, remuneration, and nomination. It has an ethical code of conduct for running its business operations and promotes a culture of trust, transparency, and accountability. Apart from fulfilling all its corporate responsibilities, the company also fulfils its environmental and social responsibilities. It complies with international best practices and guidelines to create a sustainable business. It aims to minimize the impact of its business activities on the environment and create long-term and meaningful value for all.
Bioventix PLC 7 Romans Business Park, East Street FARNHAM GU9 7SX United Kingdom GBR
+44 125 272 8001